Phase II trial of bortezomib in KRAS G12D mutant lung cancers.

摘要: e19002 Background: KRAS mutations are the most common oncogenic drivers in lung cancers without any approved targeted therapy. Preclinical evidence suggests that highly dependent on NF-kB pathway. Bortezomib, a proteasome inhibitor, has been shown to downregulate pathway and lead objective responses patients with G12D early phase clinical trials. In this single-institution, II study we assessed efficacy safety of subcutaneous bortezomib mutant cancers. Methods: Patients advanced were eligible. Bortezomib was administered at 1.3mg/m2/dose subcutaneously days 1, 4, 8, 11 21 day cycle until disease progression or unacceptable toxicity. The primary radiographic response rate (RECIST version 1.1). secondary endpoints free survival (PFS) overall (OS) determined from date first treatment. Simon two-stage minimax design used ...